Allison Willis and her sons, Nolan and Jack (15), who participated in the clinical trials for the exon-skipping drug Exondys 51 (eteplirsen), react to the FDA’s approval and expanded use of the drug. The drug treats Duchenne muscular dystrophy.

Watch the video of their story and the groundbreaking clinical trial that made history: